IN a pristine laboratory, a vial of my blood is spinning around in a roaring turbine that sounds like five washing machines going off.
An hour later, I’m handed a simple report that spells out whether or not I’ve had coronavirus. And I can’t help but feel surprised.
I’m here in Whitechapel, East London, for the launch of a state-of-the-art new antibody test, one that – along with others like it – could be the key to unlocking Britain’s ravaged economy.
“The thinking is that as you come out of lockdown, this is one mechanism that could be used to help remove restrictions,” explains Adam French, lab director of hVIVO, the company launching their test today.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).
